Clearmind Medicine Inc (CMND) - News Archive

Clearmind Medicine Inc. has recently received approval to commence its Phase I/IIa clinical trial for CMND-100, a unique psychedelic called MEAI, aimed at treating Alcohol Use Disorder (AUD). This groundbreaking develop...

Clearmind Medicine, a pioneering pharmaceutical company focused on innovative solutions for addiction treatment, has recently announced an exclusive, long-term licensing agreement with a top-notch Israeli research cente...

Clearmind Medicine Inc., a biotech company dedicated to the discovery and development of innovative psychedelic-derived therapies, recently announced the closure of its registered direct offering, raising approximately...

Clearmind Medicine Inc., a biotech company with a primary focus on the discovery and development of novel psychedelic-derived therapeutics, recently announced the pricing of its $2.4 million registered direct offering a...

Clearmind Medicine Inc. recently announced a significant milestone in their mission to revolutionize mental health treatment. The biotech company completed a Type A meeting with the U.S. Food and Drug Administration (FD...

Clearmind Medicine: Achieving Breakthrough Results in Cocaine Addiction TreatmentTel Aviv, Israel / Vancouver, Canada, Dec. 05, 2023 - Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY), known for its focus on the...

In a recent press release, Clearmind Medicine Inc. has announced a 1-for-30 reverse share split. This strategic decision is expected to significantly impact the number of outstanding shares, potentially influencing the...

Clearmind Medicine Raises US$2.25 Million in US-only Public OfferingTel Aviv, Israel / Vancouver, Canada, Sept. 14, 2023 - Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY), a biotech company dedicated to d...